25 research outputs found
Assay strategies for the discovery and validation of therapeutics targeting <i>Brugia pahangi</i> Hsp90
The chemotherapy of lymphatic filariasis relies upon drugs such as diethylcarbamazine and ivermectin that largely target the microfilarial stages of the parasite, necessitating continued treatment over the long reproductive life span of the adult worm. The identification of compounds that target adult worms has been a long-term goal of WHO. Here we describe a fluorescence polarization assay for the identification of compounds that target Hsp90 in adult filarial worms. The assay was originally developed to identify inhibitors of Hsp90 in tumor cells, and relies upon the ability of small molecules to inhibit the binding of fluorescently labelled geldanamycin to Hsp90. We demonstrate that the assay works well with soluble extracts of Brugia, while extracts of the free-living nematode C. elegans fail to bind the probe, in agreement with data from other experiments. The assay was validated using known inhibitors of Hsp90 that compete with geldanamycin for binding to Hsp90, including members of the synthetic purine-scaffold series of compounds. The efficacy of some of these compounds against adult worms was confirmed in vitro. Moreover, the assay is sufficiently sensitive to differentiate between binding of purine-scaffold compounds to human and Brugia Hsp90. The assay is suitable for high-throughput screening and provides the first example of a format with the potential to identify novel inhibitors of Hsp90 in filarial worms and in other parasitic species where Hsp90 may be a target
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
BackgroundDisorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021.MethodsWe estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined.FindingsGlobally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer.InterpretationAs the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed
Heat Shock Protein 70 Inhibitors. 1. 2,5′-Thiodipyrimidine and 5‑(Phenylthio)pyrimidine Acrylamides as Irreversible Binders to an Allosteric Site on Heat Shock Protein 70
Heat shock protein 70 (Hsp70) is
an important emerging cancer target
whose inhibition may affect multiple cancer-associated signaling pathways
and, moreover, result in significant cancer cell apoptosis. Despite
considerable interest from both academia and pharmaceutical companies
in the discovery and development of druglike Hsp70 inhibitors, little
success has been reported so far. Here we describe structure–activity
relationship studies in the first rationally designed Hsp70 inhibitor
class that binds to a novel allosteric pocket located in the N-terminal
domain of the protein. These 2,5′-thiodipyrimidine and 5-(phenylthio)Âpyrimidine
acrylamides take advantage of an active cysteine embedded in the allosteric
pocket to act as covalent protein modifiers upon binding. The study
identifies derivatives <b>17a</b> and <b>20a</b>, which
selectively bind to Hsp70 in cancer cells. Addition of high nanomolar
to low micromolar concentrations of these inhibitors to cancer cells
leads to a reduction in the steady-state levels of Hsp70-sheltered
oncoproteins, an effect associated with inhibition of cancer cell
growth and apoptosis. In summary, the described scaffolds represent
a viable starting point for the development of druglike Hsp70 inhibitors
as novel anticancer therapeutics
Structure–Activity Relationship in a Purine-Scaffold Compound Series with Selectivity for the Endoplasmic Reticulum Hsp90 Paralog Grp94
Grp94 is involved in the regulation
of a restricted number of proteins
and represents a potential target in a host of diseases, including
cancer, septic shock, autoimmune diseases, chronic inflammatory conditions,
diabetes, coronary thrombosis, and stroke. We have recently identified
a novel allosteric pocket located in the Grp94 N-terminal binding
site that can be used to design ligands with a 2-log selectivity over
the other Hsp90 paralogs. Here we perform extensive SAR investigations
in this ligand series and rationalize the affinity and paralog selectivity
of choice derivatives by molecular modeling. We then use this to design <b>18c</b>, a derivative with good potency for Grp94 (IC<sub>50</sub> = 0.22 ÎĽM) and selectivity over other paralogs (>100- and
33-fold for Hsp90α/β and Trap-1, respectively). The paralog
selectivity and target-mediated activity of <b>18c</b> was confirmed
in cells through several functional readouts. Compound <b>18c</b> was also inert when tested against a large panel of kinases. We
show that <b>18c</b> has biological activity in several cellular
models of inflammation and cancer and also present here for the first
time the in vivo profile of a Grp94 inhibitor